AU Patent

AU2020294308B2 — Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Assigned to Akebia Therapeutics Inc · Expires 2022-08-11 · 4y expired

What this patent protects

Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2 carbonyl]amino}acetic acid, compositions comprising thesolid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. 65

USPTO Abstract

Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2 carbonyl]amino}acetic acid, compositions comprising thesolid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders. 65

Drugs covered by this patent

Patent Metadata

Patent number
AU2020294308B2
Jurisdiction
AU
Classification
Expires
2022-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.